StageZero Life Sciences Announces OSC Denial of MCTO Application

StageZero Life Sciences Ltd. (TSX:SZLS)(OTCQB:SZLSF), a leading integrated healthcare company, today disclosed that the Ontario Securities Commission (OSC) has denied its voluntary management cease trade order (MCTO) application. This decision comes after the company's announcement on April 2, 2024, citing an expected delay in filing their audited annual financial statements and related documents for the year ended December 31, 2023. The required filings, under National Instruments 51-102 and 52-109, were missed by the April 2 deadline, potentially leading to a Failure-to-File Cease Trade Order (FFCTO) by the OSC.

The company emphasized its commitment to resolving the issue swiftly, with an anticipated document filing by May 31, 2024. StageZero is known for its innovative diagnostic solutions, including the Aristotle® test, which screens for multiple cancers from a single blood sample. They also offer unique telehealth programs targeting cancer and chronic diseases, emphasizing early detection and management.